thymic humoral factor gamma 2 profile

thymic humoral factor gamma 2: synthetic octapeptide thymic hormone which repairs immunodeficiency of mice cured of plasmacytoma by melphalan [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	9897695
CHEMBL ID	2106038
SCHEMBL ID	1230532
MeSH ID	M0177811

Synonym
thymoctonan
thymoctonan [inn]
thymic humoral factor gamma 2
l-leucine, n-(n-(n2-(1-(n-(n-(n-l-leucyl-l-alpha-glutamyl)-l-alpha-aspartyl)glycyl)-l-prolyl)-l-lysyl)-l-phenylalanyl)-
leucyl-glutamyl-aspartyl-glycyl-proly-lysyl-phenylalanyl-leucine
n-(n-(n(sup 2)-(1-(n-(n-(n-l-leucyl-l-alpha-glutamyl)-l-alpha-aspartyl)glycyl)-l-prolyl)-l-lysyl)-l-phenylalanyl)-l-leucine
leu-glu-asp-gly-pro-lys-phe-leu
unii-5027686086
107489-37-2
(-)-thymoctonan
CHEMBL2106038
thymic humoral factor-gamma 2
thf-gamma 2
SCHEMBL1230532
(s)-5-(((s)-1-((2-((s)-2-(((s)-6-amino-1-(((s)-1-(((s)-1-carboxy-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxohexan-2-yl)carbamoyl)pyrrolidin-1-yl)-2-oxoethyl)amino)-3-carboxy-1-oxopropan-2-yl)amino)-4-((s)-2-amino-4-methylpentanamido)-5-oxo
(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-1-[2-[[2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-4-hydroxy-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]hexanoyl]
h-leu-glu-asp-gly-pro-lys-phe-leu-oh
Q27231280
(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-1-[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
HY-125301
CS-0090285
AKOS040754201

Excerpt	Reference	Relevance
"We reported previously that treatment of mice bearing MOPC-315 plasmacytoma with the drugs L-PAM (phenylalanine mustard) or 5-FU (5-fluorouracil), in combination with low doses of THF-gamma 2, was more effective in increasing their survival time than treatment with the drug alone."	( Therapeutic effectiveness against MOPC-315 plasmacytoma of low or high doses of the synthetic thymic hormone THF-gamma 2 in combination with an "immunomodulating" or a "non-immunomodulating" drug. Ben-Efraim, S; Burstein, Y; Harshemesh, H; Ophir, R; Pecht, M; Trainin, N, 1991)	0.28

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (3.23)	18.7374
1990's	23 (74.19)	18.2507
2000's	5 (16.13)	29.6817
2010's	1 (3.23)	24.3611
2020's	1 (3.23)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (8.82%)	5.53%
Reviews	4 (11.76%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	27 (79.41%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.68	3	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
thymidine [no description available]	3.37	1	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	2.39	2	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
phenylalanylleucine phenylalanylleucine: RN given refers to (L)-isomer	2.25	1	0	dipeptide zwitterion; dipeptide	plant metabolite
thymopentin Thymopentin: Synthetic pentapeptide corresponding to the amino acids 32-36 of thymopoietin and exhibiting the full biological activity of the natural hormone. It is an immunomodulator which has been studied for possible use in the treatment of rheumatoid arthritis, AIDS, and other primary immunodeficiencies.	3.49	2	0	oligopeptide
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	3.08	5	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
glycylproline Gly-Pro : A dipeptide consisting of L-proline having a glycyl residue attached to its alpha-amino group.	2.25	1	0	dipeptide zwitterion; dipeptide	metabolite
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	1.98	1	0
thymalfasin Thymalfasin: A thymus hormone polypeptide found in thymosin fraction 5 (a crude thymus gland extract) but now produced by synthesis. It is used alone or with interferon as an immunomodulator for the treatment of CHRONIC HEPATITIS B and HEPATITIS C. Thymalfasin is also used for the treatment of chemotherapy-induced immunosuppression, and to enhance the efficacy of influenza and hepatitis B vaccines in immunocompromised patients.	4.31	3	0	polypeptide
thymosin Thymosin: Thymosin. A family of heat-stable, polypeptide hormones secreted by the thymus gland. Their biological activities include lymphocytopoiesis, restoration of immunological competence and enhancement of expression of T-cell characteristics and function. They have therapeutic potential in patients having primary or secondary immunodeficiency diseases, cancer or diseases related to aging.	4.7	5	0
tuftsin Tuftsin: N(2)-((1-(N(2)-L-Threonyl)-L-lysyl)-L-prolyl)-L-arginine. A tetrapeptide produced in the spleen by enzymatic cleavage of a leukophilic gamma-globulin. It stimulates the phagocytic activity of blood polymorphonuclear leukocytes and neutrophils in particular. The peptide is located in the Fd fragment of the gamma-globulin molecule.	1.99	1	0	peptide
thymic factor, circulating Thymic Factor, Circulating: A thymus-dependent nonapeptide found in normal blood. Stimulates the formation of E rosettes and is believed to be involved in T-cell differentiation.	1.98	1	0
ganciclovir [no description available]	6.99	1	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug

Condition	Relationship Strength	Studies	Trials
Chronic Delta Hepatitis [description not available]	3.35	2	0
Uremia A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.	4.48	5	1
Chronic Illness [description not available]	3.77	2	1
Hepatitis B Virus Infection [description not available]	3.77	2	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	3.77	2	1
Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	3.77	2	1
Cytomegalic Inclusion Disease [description not available]	2.39	2	0
Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.	2.39	2	0
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	1.98	1	0
Cancer of the Thymus [description not available]	1.98	1	0
Thymus Neoplasms Tumors or cancer of the THYMUS GLAND.	1.98	1	0
Adverse Drug Event [description not available]	1.99	1	0
Cancer of Lung [description not available]	2.39	2	0
Metastase [description not available]	1.99	1	0
Experimental Neoplasms [description not available]	1.99	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.39	2	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	1.99	1	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	1.99	1	0
Infectious Diseases [description not available]	3.37	1	1
Communicable Diseases An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.	3.37	1	1
Carcinoma, Lewis Lung A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.	1.99	1	0
Acute Disease Disease having a short and relatively severe course.	1.99	1	0
Benign Neoplasms [description not available]	3.78	2	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.78	2	0
Amazon Black Fever [description not available]	2.01	1	0
Hepatitis D INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	2.01	1	0
Antibody Deficiency Syndrome [description not available]	3.58	3	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	1.98	1	0
Immunologic Deficiency Syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.	3.58	3	0
Plasma Cell Tumor [description not available]	2.67	3	0
Plasmacytoma Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.	2.67	3	0
Autoimmune Disease [description not available]	2.89	1	0
Viral Diseases [description not available]	2.89	1	0
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	2.89	1	0
Virus Diseases A general term for diseases caused by viruses.	2.89	1	0

thymic humoral factor gamma 2

Description

Cross-References

Synonyms (22)

Research Excerpts

Compound-Compound Interactions

Research

Studies (31)

Market Indicators

Research Demand Index: 12.40

Study Types